
Biocon shares may get a boost after the US drug regulator approves key diabetes treatment drug
The FDA approval of Kristy expands Biocon Biologics’ biosimilar insulin portfolio, which also includes the first approved interchangeable biosimilar, Semglee (Insulin Glargine-yfgn injection).








